Top Abstracts of Interest at the ASH 2022 Myeloma Sessions

In this week’s blog, IMF Chairman of the Board and Chief Scientific Officer Dr. Brian G.M. Durie discusses top abstracts of interest during the American Society of Hematology (ASH) 2022 Annual Meeting in New Orleans, Louisiana. He reports on the results of talquetamab-related abstracts; presentations on other bispecific trials; a new dual target CAR T therapy frontline from Shanghai, China; findings of the iStopMM study abstracts; as well as results of the ASCENT, CESAR, MRD Testing, and dexamethasone sparing trials. With numerous new and promising observations from ASH 2022 bringing great hope, Dr. Durie is optimistic about the immediate future for myeloma.

Register for the Top Myeloma Research Presented at ASH 2022 Webinar

The “Top Myeloma Research Presented at ASH 2022: What Patients and Care Partners Need to Know” webinar will take place on Tuesday, December 20, 2022, at 4:00 p.m. PST | 5:00 p.m. MST | 6:00 p.m. CST | 7:00 p.m. EST. In this webinar, IMF Chairman of the Board and Chief Scientific Officer Dr. Brian G. M. Durie will summarize key takeaways from the 2022 American Society of Hematology (ASH) Annual Meeting that impact the myeloma community. Additionally, Dr. Durie will host a panel discussion highlighting the patient perspective with Linda Huguelet, IMF Support Group Leader of Chattanooga, TN; and Nick Lenoir, IMF Support Group Co-leader of Brooksville, FL. Both Linda and Nick are attending this year’s ASH annual meeting.

The IMF Welcomes You into 2023

The IMF welcomes you into 2023 with love, guidance, and support from our IMF family to yours. We encourage you to lean into the season’s giving spirit, celebrate traditions of togetherness, and have a happy, healthy new year. In the spirit of the holidays, we would like to share some downloadable gifts to help you more easily navigate myeloma treatment options. Visit the page below for these gifts and learn how you can continue to support our mission to improve the quality of lives of myeloma patients while working toward prevention and a cure.

Now Available: The Fall 2022 Edition of Myeloma Today

The latest digital edition of Myeloma Today is now interactive — with many helpful hyperlinks to a broad range of resources. In the Fall 2022 edition, IMF Chief Medical Officer Dr. Joseph Mikhael gives an overview of TECVAYLI™(teclistamab-cqyv), the first-in-class bispecific BCMA-directed CD3 T-cell engager that has been granted accelerated approval by the FDA for the treatment of adult patients with relapsed or refractory myeloma. Also included is a summary of treatment options for patients with myeloma after 1–3 prior lines of therapy and treatment with CAR T after 4 or more prior lines of therapy, and more. Myeloma Today is available to download for FREE. Medical articles are translated and available in French, Italian, German, and Spanish.

Myeloma Treatment Options in Early Relapse

IMF Chief Medical Officer Dr. Joseph R. Mikhael writes about treatment options for early relapsed myeloma patients, highlighting five key clinical trials including the IKEMA trial, the APOLLO trial, the BOSTON trial, the CANDOR trial, and the ICARIA trial. Read his blog now to learn about how there are more treatment options available for early relapsed myeloma patients than ever before.

Connect with IMF Support Group Leaders Through Their Blogs on ASH 2022

The IMF brought myeloma support group leaders and patients to the hybrid 64th annual meeting of the American Society of Hematology (ASH), an exciting convergence of 10,000 health care professionals from around the world. If you haven’t yet, follow these IMF ASH team members as they blog and tweet about the latest clinical updates in myeloma research, therapies, and practice strategies. Visit the ASH Blogs site now.

First in a Series of Videos from Myeloma Experts, Filmed Live at ASH 2022

The IMF talks with leading myeloma experts live from the 64th American Society of Hematology Annual Meeting & Exposition. Visit all of IMF’s coverage from ASH at mmsm.link/ASH, and view this one from Dr. Ben Derman (University of Chicago) as he presents a report on the prospective MRD2STOP study.

#ASKDRDURIE | Dr. Durie's Weekly Web Video Series

Is the IMF’s ASCENT trial curing smoldering myeloma patients?

“We are quite optimistic that a number of these patients will indeed have sustained MRD-negative status and may end up indeed being cured by this early aggressive intervention.” — Dr. Brian G.M. Durie